Clinical Trial

Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of BAFF-R CAR-T Cells in Adult Subjects with CD19-Negative relapsed or refractory B-Cell Lymphoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-18; most recent amendment 2026-02-25.
Trial Details
NCT Number NCT07369492
Lead Sponsor Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Conditions B-cell Lymphoma
Enrollment 30 participants
Start Date 2026-01-01
Primary Completion 2027-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-27